Sign Out
Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT and/or IFG*, and/or increased HbA1c who are: at high risk for developing overt type 2 diabetes mellitus and still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.
Treatment with Metformin HCl PR tablet must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk.
Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.
*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose: Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. Metformin HCl PR tablet may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.
Continue with Google